Compare ANIX & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | IAF |
|---|---|---|
| Founded | 1982 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.9M | 121.1M |
| IPO Year | 2013 | N/A |
| Metric | ANIX | IAF |
|---|---|---|
| Price | $3.00 | $12.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $9.67 | N/A |
| AVG Volume (30 Days) | ★ 203.7K | 49.9K |
| Earning Date | 09-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.44% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $11.76 |
| 52 Week High | $5.46 | $14.54 |
| Indicator | ANIX | IAF |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 41.25 |
| Support Level | $2.77 | $12.27 |
| Resistance Level | $3.09 | $12.87 |
| Average True Range (ATR) | 0.18 | 0.22 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 47.65 | 8.51 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Abrdn Australia Equity Fund Inc is a non-diversified closed-end management investment company. The Fund's principal investment objective is long-term capital appreciation through investment in equity securities of Australian companies listed on the Australian Stock Exchange Limited (ASX). Its secondary objective is current income, which is expected to be derived from dividends and interest on Australian corporate and governmental securities.